Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16109346 | 0.92 | SCN9A (0.48) | SCN9AMEN1KMT2ATP53TAS2R14 | |
| SCHEMBL1109044 | 0.90 | SCN9A (0.47) | SCN9AMEN1KMT2ATP53TAS2R14 | |
| SCHEMBL1095344 | 0.89 | SCN9A (0.46) | SCN9AMEN1KMT2ATP53TAS2R14 | |
| SCHEMBL29669273 | 0.89 | SCN9A (0.46) | SCN9AMEN1KMT2ATP53TAS2R14 | |
| SCHEMBL17048645 | 0.88 | SCN9A (0.49) | SCN9AMEN1KMT2ATP53TAS2R14 | |
| SCHEMBL14921517 | 0.87 | SCN9A (0.45) | SCN9AMEN1KMT2ATP53POLB | |
| SCHEMBL31093304 | 0.87 | SCN9A (0.45) | SCN9A | |
| SCHEMBL319158 | 0.87 | SCN9A (0.45) | SCN9A | |
| SCHEMBL14699068 | 0.87 | SCN9A (0.46) | SCN9AMEN1KMT2APOLBGAA | |
| SCHEMBL30479339 | 0.85 | SCN9A (0.43) | SCN9AMEN1KMT2ATP53TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-9145407-B2 | Sulfonamide compounds | PFIZER LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| EP-2590972-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| EP-2590972-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2015-01-21 | — | — | EP | disclosed |
| WO-2014170793-A1 | SULFONAMIDES FOR THE TREATMENT OF GOUT | PFIZER LIMITED (GB) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315933-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| EP-2590972-A2 | CHEMICAL COMPOUNDS | Pfizer Limited (GB) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| US-20130109667-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012004706-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315933-A1 | CHEMICAL COMPOUNDS | SULT2A1, SULT1A1, SULT1E1 | SCN9A 1724/4885MEN1 3205/4885KMT2A 1586/4885 |
| US-20130109667-A1 | Chemical Compounds | SCN1A, SCN7A, SCN1B | SCN9A 11/4885MEN1 3101/4885KMT2A 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.